<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02078947</url>
  </required_header>
  <id_info>
    <org_study_id>EU 602405-2</org_study_id>
    <nct_id>NCT02078947</nct_id>
  </id_info>
  <brief_title>Optimizing Exercise Training in Prevention and Treatment of Diastolic Heart Failure</brief_title>
  <acronym>OptimEx-Clin</acronym>
  <official_title>Optimizing Exercise Training in Prevention and Treatment of Diastolic Heart Failure- Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Leipzig</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Antwerp</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Norwegian University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Technische Universität München</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of the clinical multicenter study (OptimEx-CLIN) is to assess the optimal exercise
      intervention in patients with Heart Failure with preserved Ejection Fraction (HFpEF; also
      termed diastolic heart failure) that will best improve peak oxygen uptake (Peak Vo2) and
      additionally diastolic function (assessed echocardiographically). The investigators
      hypothesize that exercise training reverses HFpEF and that intensity of exercise training is
      more important than duration.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Peak VO2 after three months</measure>
    <time_frame>Baseline and three months</time_frame>
    <description>Change in Peak VO2 after three month intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in E/e' (representing diastolic filling pressure) at baseline and three months</measure>
    <time_frame>three months</time_frame>
    <description>Change in E/e' (representing diastolic filling pressure) at baseline and three months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in E/e' at baseline and 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Change in E/e' at baseline and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Peak VO2 at baseline and 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Change in Peak VO2 at baseline and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in NTproBNP at baseline and three months</measure>
    <time_frame>three months</time_frame>
    <description>Change in NTproBNP at baseline and three months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in NTproBNP at baseline and 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Change in NTproBNP at baseline and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in health related quality of life at baseline and three months</measure>
    <time_frame>three months</time_frame>
    <description>Change in HRQOL as measured by the Kansas City Cardiomyopathy Questionnaire at baseline and three months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in health related Quality of life at baseline and 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Change in HRQOL as measured by the Kansas City Cardiomyopathy Questionnaire at baseline and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Left Atrial Volume Index (LAVI) at baseline and three months</measure>
    <time_frame>three months</time_frame>
    <description>Change in Left Atrial Volume Index (LAVI) at baseline and three months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Left Atrial Volume Index (LAVI) at baseline and 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Change in Left Atrial Volume Index (LAVI) at baseline and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in e' medial at baseline and three months</measure>
    <time_frame>three months</time_frame>
    <description>Change in e' medial at baseline and three months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in e' at baseline and 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Change in e' at baseline and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in submaximal exercise capacity at baseline and three months</measure>
    <time_frame>three months</time_frame>
    <description>submaximal exercise capacity will be measured using watts at the first ventilatory threshold (VT1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in submaximal exercise capacity at baseline and 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Submaximal exercise capacity will be measured using watts at the first ventilatory threshold (VT1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in VE/VCO2 slope at baseline and three months</measure>
    <time_frame>three months</time_frame>
    <description>Change in VE/VCO2 slope at baseline and three months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in VE/VCO2 slope at baseline and 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Change in VE/VCO2 slope at baseline and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Flow Mediated Dilation (FMD) at baseline and three months</measure>
    <time_frame>three months</time_frame>
    <description>Change in Flow Mediated Dilation (FMD) at baseline and three months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Flow Mediated Dilation (FMD) at baseline and 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Change in Flow Mediated Dilation (FMD) at baseline and 12 months</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Heart Failure With Preserved Ejection Fraction</condition>
  <arm_group>
    <arm_group_label>High Intensity Exercise</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients perform interval- type endurance exercise at high intensity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate Continuous Exercise</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients perform endurance exercise at moderate intensity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patients receive advice on being physically active as well as usual care</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>High Intensity Exercise</intervention_name>
    <arm_group_label>High Intensity Exercise</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Moderate Continuous Exercise</intervention_name>
    <arm_group_label>Moderate Continuous Exercise</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Usual Care</intervention_name>
    <arm_group_label>Usual Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sedentary (structured exercise &lt; 2x 30 min/wk)

          -  At least 40 years old

          -  Preserved systolic function LVEF &gt; 50%

          -  Signs and symptoms of heart failure class NYHA II or III

          -  Diastolic dysfunction (E/é &gt; 15 or E/é 8-15 and NT-proBNP &gt; 220 pg/ml)

          -  Clinically stable for &gt;= 6 weeks

          -  Optimal medical treatment for &gt;= 6 weeks

          -  Written informed consent

        Exclusion Criteria:

          -  Non- HFpEF causes for HF symptoms (significant valvular or coronary disease,
             uncontrolled hypertension or arrhythmias, primary cardiomyopathies)

          -  Significant pulmonary disease (FEV1 &lt; 50% predicted, COPD GOLD III-IV)

          -  Inability to exercise or conditions that may interfere with exercise intervention

          -  Myocardial infarction in the previous three months

          -  Signs of ischemia during exercise testing

          -  Comorbidity that may influence one- year prognosis

          -  Participation in another clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Halle, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Technische Universität München, Munich, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Halle, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Technische Universität München, Munich, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Burkert Pieske, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christiaan Vrints, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Antwerp University Hospital, Belgium</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Volker Adams, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heart Center Leipzig, Leipzig, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ulrik Wisløff, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Norwegian University of Science and Technology, Trondheim, Norway</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Axel Linke, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heart Center Leipzig, Leipzig, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frank Edelmann, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Cardiology, Antwerp University Hospital</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Innere Medizin/ Kardiologie, Herzzentrum Leipzig- Universitätsklinik</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Prevention, Rehabilitation and Sports Medicine, Technische Universität München</name>
      <address>
        <city>Munich</city>
        <zip>80992</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
  </location_countries>
  <removed_countries>
    <country>Austria</country>
    <country>Norway</country>
  </removed_countries>
  <link>
    <url>http://www.ntnu.edu/optimex</url>
  </link>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2014</study_first_submitted>
  <study_first_submitted_qc>March 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2014</study_first_posted>
  <last_update_submitted>May 30, 2017</last_update_submitted>
  <last_update_submitted_qc>May 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diastolic heart failure, Heart failure with preserved ejection fraction, exercise</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Failure, Diastolic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

